Roy D. Baynes, Director at Travere Therapeutics, Inc. (TVTX), sold 32,750 shares at $41.07 ($1.4M) on 2026-04-14, disclosed to the SEC on 2026-04-16.
Scheduled sale ($1.4M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.07 | 26,000 | $1.1M | 79.0% |
| 2 | $42.12 | 6,750 | $284K | 21.0% |
| Total | $41.29 avg | 32,750 | $1.4M | 100% |
| Filing → |
| TVTX | SELL | 2026-05-04 | $431K | — | Filing → |
| TVTX | SELL | 2026-04-07 | $330K | — | Filing → |
| NTRA | SELL | 2025-11-21 | $4.6M | — | Filing → |